VolitionRx Unveils Promising Data: Nu.Q® Immunoassay Detects 21 Cancers, Eyes Multi-Licensing Deals

VolitionRx Limited (NYSE AMERICAN: VNRX) ('Volition'), a multi-national epigenetics company, announces the results of a study which shows that an automated Nu.Q® Cancer immunoassay test in development detected a range of 21 different cancers. This could potentially be used as a standalone pan-cancer test or, given its low false positive rate among healthy people, be licensed out for use in conjunction with other liquid biopsy technologies to improve accuracy.

Gael Forterre, Chief Commercial Officer at Volition, commented:

"Our mission since the company was incorporated was to help detect cancer early, with the aim of saving lives and improving outcomes.

"We are excited to publish this further validation of our Nu.Q® platform; it represents a potential opportunity to disrupt the $20 billion Total Annual Accessible Market for liquid biopsy for multi-cancer early detection in the U.S.¹.

"We are in active discussions regarding our cancer portfolio with several large diagnostic and liquid biopsy companies, with the goal of signing multiple licensing agreements this year, including milestone payments in addition to ongoing revenue.

"Volition's nucleosome assays can be run on existing automated chemiluminescence platforms worldwide and do not need new hardware. Our commercial strategy is to leverage this base to make Nu.Q® Cancer testing accessible to patients as widely as possible on existing platforms through licensing and partnership arrangements."